DrugPatentWatch Database Preview
Eli Lilly And Co Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has seven approved drugs.
There are fourteen US patents protecting ELI LILLY AND CO drugs.
There are two hundred and nineteen patent family members on ELI LILLY AND CO drugs in fifty-one countries and thirty-three supplementary protection certificates in sixteen countries.
Summary for Eli Lilly And Co
| International Patents: | 219 |
| US Patents: | 14 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for Eli Lilly And Co: | See patent lawsuits for Eli Lilly And Co |
| PTAB Cases with Eli Lilly And Co as petitioner: | See PTAB cases with Eli Lilly And Co as petitioner |
| PTAB Cases with Eli Lilly And Co as patent owner: | See PTAB cases with Eli Lilly And Co as patent owner |
Drugs and US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-001 | Jul 10, 2009 | AB | RX | Yes | No | Start Trial | Start Trial | ||||
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | DISCN | Yes | No | 8,993,520 | Start Trial | Start Trial | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-002 | Oct 8, 2019 | RX | Yes | No | Start Trial | Start Trial | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | 7,423,050 | Start Trial | Y | Y | Start Trial | ||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | 8,158,616 | Start Trial | Y | Y | Start Trial | ||
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-003 | Jun 15, 1999 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,083,982 | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-003 | Jun 15, 1999 | 4,314,081*PED | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,035,511 | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-006 | Dec 23, 1992 | 4,018,895 | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-006 | Dec 23, 1992 | 4,314,081*PED | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,018,895 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-07-10 |
International Patents for Eli Lilly And Co Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2018507852 | Start Trial |
| Israel | 253273 | Start Trial |
| Japan | 6522144 | Start Trial |
| Japan | 2010515490 | Start Trial |
| Germany | 60308850 | Start Trial |
| Mexico | 2009007366 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eli Lilly And Co Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | 2017/032 | Ireland | Start Trial | PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2288610 | 17C0005 | France | Start Trial | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
| 2379528 | LUC00106 | Luxembourg | Start Trial | PRODUCT NAME: ABEMACICLIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VERZENIOS); AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| 2379528 | 2019009 | Norway | Start Trial | PRODUCT NAME: ABEMACIKLIB ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1307 20180927 |
| 2379528 | 2019C/507 | Belgium | Start Trial | PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| 0542411 | C300397 | Netherlands | Start Trial | PRODUCT NAME: PRASUGREL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
